Navigation Links
Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Date:6/2/2010

EAST HANOVER, N.J., June 3 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that a Phase III study of Afinitor® (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors), is part of the largest clinical trial program of its kind.

Everolimus is approved under the trade name Afinitor® (everolimus) tablets for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.

Pancreatic NET can grow aggressively and at time of diagnosis nearly 60% of all patients have advanced disease, meaning the cancer has spread to other parts of the body and has become more difficult to treat(1),(2). The median survival rate for patients with advanced pancreatic NET is 17 months(2). Currently, surgery and chemotherapy are the only approved treatment options for patients with advanced pancreatic NET(1).

"Everolimus was developed to inhibit the mTOR protein, which is a critical target in treating various cancers, including NET. Results from RADIANT-3 demonstrate that everolimus has the potential to become an important treatment option for patients with advanced pancreatic NET, where there is a major unmet need," said Herve Hoppenot, President, Novartis Oncology. "These study results will serve as the basis of worldwide regulatory filings for everolimus and bring us one step closer to our goal of offering these patients a new therapy."

Full results
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Decision Resources Group finds that, for the treatment ... France , Germany , ... and the United Kingdom ) hold ... beta2 agonist/inhaled corticosteroid (LABA/ICS) fixed-dose combination (FDC), Relvar (GlaxoSmithKline/Theravance). ... first-line LABA/ICS FDC in the treatment of asthma with ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- "North America ... key market data on the North America Orthopedic Braces ... of US dollars, and volume (in units) and average ... , Knee Braces and Supports , Ankle ... , Upper Extremities Braces and Supports. ...
(Date:7/24/2014)... 24, 2014 Boston Children,s Hospital,s Global Pediatric ... will feature an "Innovation Tank" – a forum designed ... pitch their business or product solution to a panel ... on how to accelerate the innovation and bring it ... of Friday, October 31, will be moderated by ...
Breaking Medicine Technology:Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3
... 2011 /PRNewswire-Asia-FirstCall/ -- Financial Highlights for the ... increased 40.8% to $7.68 million Gross profit increased 30.1% to ... 14.2% to $3.90 million, representing a net margin of 50.8% ... Financial Highlights for the Six Months Ended June ...
... Mylan Inc. (Nasdaq: MYL ) today announced that ... Tablets, 10 mg. This product is the generic version of ... hyperplasia, or an enlarged prostate. Uroxatral® Tablets ... months ending June 30, 2011, according to IMS Health. ...
Cached Medicine Technology:Nutrastar Announces Second Quarter 2011 Financial Results 2Nutrastar Announces Second Quarter 2011 Financial Results 3Nutrastar Announces Second Quarter 2011 Financial Results 4Nutrastar Announces Second Quarter 2011 Financial Results 5Nutrastar Announces Second Quarter 2011 Financial Results 6Nutrastar Announces Second Quarter 2011 Financial Results 7Nutrastar Announces Second Quarter 2011 Financial Results 8Nutrastar Announces Second Quarter 2011 Financial Results 9Nutrastar Announces Second Quarter 2011 Financial Results 10Nutrastar Announces Second Quarter 2011 Financial Results 11
(Date:7/24/2014)... July 24, 2014 Dr. Kwame Bawuah ... the workshop with an admonition to the youth to ... in life. He also advised the youth to stay ... sex. He said, “This workshop will afford you the ... you to withstand the storms in your career path.” ...
(Date:7/24/2014)... 24, 2014 The first-ever successful isolation ... patient’s blood has been achieved by NFCR-supported scientist Daniel ... Hospital. This is an important milestone on the road ... the best treatment for each patient. , “Tumors ... often acquire new genetic features that make them resistant ...
(Date:7/24/2014)... the patient or their tumor more directly to ionizing ... damages the cancer cells irreparably. Unfortunately, such radiation is ... the site of the tumor, which is then at ... cancer. As such finding ways to protect the overlying ... Journal of Low Radiation, Faruck Lukmanul Hakkim of the ...
(Date:7/24/2014)... have uncovered a way the malaria parasite becomes ... Washington University School of Medicine in St. Louis, ... bacterial infections and tuberculosis. , The study appears ... Many organisms, including the parasite that causes malaria, ... play multiple roles in keeping organisms healthy, whether ...
(Date:7/24/2014)... Charlotte, NC (PRWEB) July 24, 2014 ... donated over $138,000 in sealant and anesthesia reversal ... ToothFairy® (NCOHF) to help save young smiles. The ... Sealant Kits and Oraverse® was distributed to America’s ... the U.S. with vital oral health services. The ...
Breaking Medicine News(10 mins):Health News:Youth and Professionals Interact at Washington Metro Area Career Workshop Hosted by the Edusei Foundation 2Health News:New Blood Test Advances Individualized Cancer Therapy and Cuts Down on Need for Painful Biopsies 2Health News:Natural products from plants protect skin during cancer radiotherapy 2Health News:One route to malaria drug resistance found 2Health News:One route to malaria drug resistance found 3Health News:Septodont Donation Helps Children in Need 2
... responsible for a form of the herpes virus that causes ... causes purple skin blotches and can also attack the internal ... disease defenses but attacks those with weakened immune system as ... 8 was discovered six years ago. Almost 30% to 50% ...
... not reduce ,the risk of cardiac events ... disease (CAD). In the PHASE trial (Papworth ... women with angiographically proven coronary ,artery disease ... without cyclic norethisterone--or no hormone replacement therapy. ...
... Lunelle-a monthly injectable contraceptive pill has been approved by ... is more than 99 percent effective when women get ... release marketing the pill., ,Lunelle is an alternative ... months. It works Like many other birth control pills ...
... overall long-term survival rates in both men and women. Their ... ,Researchers studied survival rates based on a lung function ... the lung function test on a group of more than ... age from 20 to 89 years at enrollment. They have ...
... In some of the cancer patients the Tumors can't be ... using vitamin B12 that helps doctors locate hard to find ... vitamin B12. After three hours a gamma camera takes pictures ... cancer and he says that, "The cancer stands out as ...
... The American Heart Association announced it has revised ... of ,cardiovascular emergencies., ,Untrained bystanders and CPR-certified ... an unconscious person's pulse before administering chest compressions. ... breath, movement and response to stimulation as indicators. ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: